+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 42 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are evaluating sacituzumab tirumotecan alone or combined with pembrolizumab to treat people with triple-negative breast cancer TNBC that is locally recurrent, unresectable, or metastatic and expresses PD-L1 at a combined positive score less than 10. The study aims to find out if these treatments help people live longer overall or delay cancer growth compared to chemotherapy chosen by their physician. This is a phase 3 randomized trial focused on treatment effectiveness and safety. Participants are randomly assigned to one of three groups sacituzumab tirumotecan given intravenously every two weeks sacituzumab tirumotecan every two weeks plus pembrolizumab every six weeks for up to about two years or physicians choice chemotherapy including options like paclitaxel, nab-paclitaxel, gemcitabine plus carboplatin with varying schedules. Pre-medications such as antihistamines, acetaminophen, and steroids are given before sacituzumab tirumotecan infusions to reduce side effects. During the study, participants receive assigned treatments until disease progression, toxicity, or discontinuation. Researchers monitor progression-free survival and overall survival up to about 39 and 61 months respectively. They also assess response rates, duration of response, quality of life changes using questionnaires, and record adverse events over the study period. The trial follows participants for extended periods to evaluate long-term outcomes and safety.

Age: 18Years +All GendersPhase 3
283 locations
C

Actively Recruiting

Researchers are evaluating the effectiveness of Pumitamig compared to Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer NSCLC who have a PD-L1 expression of 50% or higher. This Phase 3, randomized, double-blind study focuses on participants with locally advanced or metastatic NSCLC, aiming to understand which treatment better controls the disease and improves survival outcomes. Participants are randomly assigned to receive either Pumitamig or Pembrolizumab at specified doses on specified days. The study compares these two drugs as first-line treatments for their impact on disease progression and overall survival. The treatment period may last up to approximately five years to assess long-term outcomes. During the study, participants will undergo regular assessments including imaging and symptom questionnaires to evaluate progression-free survival and overall survival. Researchers will also monitor objective response, duration of response, disease control rate, and symptom changes using established criteria. Safety and effectiveness will be closely followed throughout the study, which lasts up to about five years from enrollment.

Age: 18Years +All GendersPhase 3
283 locations
E

Actively Recruiting

Researchers are evaluating the combination of vicadrostat BI 690517 and empagliflozin for adults aged 18 and older who have heart failure symptoms and a left ventricular ejection fraction LVEF of 40% or more. The study aims to find out whether taking vicadrostat with empagliflozin helps people with heart failure. This is a phase III randomized, double-blind, parallel-group trial sponsored by Boehringer Ingelheim. Participants are randomly assigned to one of two groups one group takes vicadrostat combined with empagliflozin tablets once daily, and the other group takes a placebo combined with empagliflozin tablets once daily. The study has no fixed duration participants can stay in the study as long as they benefit from treatment and can tolerate it. During the study, participants visit their doctors regularly for health checks and monitoring. Throughout the study, participants undergo regular health assessments including monitoring for any unwanted effects. Study staff may also contact participants by phone and ask them to answer questions about their well-being. The main outcome being measured is the time to the first event of cardiovascular death, hospitalization for heart failure, or urgent heart failure visit over up to 42 months. Other outcomes include symptom scores, blood pressure changes, and kidney function. The study runs until enough data is collected to evaluate the treatments effects.

Age: 18Years +All GendersPhase 3
671 locations
C

Actively Recruiting

Healthy Volunteer

Carpal Tunnel Syndrome is a common condition that causes symptoms like tingling, pain, numbness, and weakness. Surgery called carpal tunnel release is the most effective treatment. This research compares two types of sutures used to close wounds after surgery absorbable and non-absorbable to see if one type affects the chance of wound infection. The study is a randomized controlled trial investigating how sutures influence infections after surgery. Participants will receive carpal tunnel release surgery where the flexor retinaculum is cut to relieve pressure. After surgery, wounds will be closed using either absorbable sutures Vicryl rapide or Safil quick or non-absorbable sutures Ethilon or Flexocrin. Both suture types are commonly used, but this study aims to find if one leads to fewer infections. The trial does not use masking, and participants are randomly assigned to one of the two suture groups. During the study, researchers will assess wound healing using the ASEPSIS wound score between 10 and 14 days after surgery. Patients will also record their pain using a Numeric Rating Scale for up to three weeks after surgery. Use of antibiotics, hand therapy, and any extra doctor visits will be recorded. The study is sponsored by Gelre Hospitals and includes adult participants aged 18 and older. Participation may last several weeks for follow-up and assessments.

Age: 18Years +All GendersPhase Not Applicable
2 locations
S

Actively Recruiting

This research aims to compare the effects of oral anticoagulation versus no anticoagulation in patients aged 55 and older who have had recent episodes of transient atrial fibrillation triggered by stress and have additional factors that increase their risk of stroke. The study is a multinational, investigator-initiated, prospective, randomized, open-label trial evaluating the impact of non-vitamin K oral anticoagulants NOACs on preventing stroke and other serious cardiovascular events. Participants will be randomly assigned to either receive one of several NOACs, such as edoxaban, apixaban, dabigatran, or rivaroxaban, prescribed by their physician for the duration of the follow-up, or to a control group that will not receive anticoagulants unless medically indicated during the study. The choice of specific NOAC and dose adjustments are determined by the prescribing doctor. The study excludes patients with certain conditions like chronic atrial fibrillation, severe kidney or liver disease, recent cardiac surgery, or bleeding risks. During the study, participants will be monitored for up to 24 months to assess the occurrence of non-hemorrhagic stroke, systemic embolism, vascular mortality, myocardial infarction, peripheral arterial thrombosis, amputation, and venous thromboembolism. Regular follow-up will include evaluation of these outcomes to measure the effectiveness and safety of anticoagulation compared to no anticoagulation. Participants will provide informed consent and remain under medical supervision throughout the trial.

Age: 55Years +All GendersPhase 4
105 locations
S

Actively Recruiting

Researchers are evaluating a shorter treatment duration with androgen receptor pathway inhibitors ARPIs, specifically Apalutamide or Enzalutamide, in patients with low-volume hormone-sensitive metastatic prostate cancer. This phase 3 clinical trial aims to determine if stopping ARPI therapy after 12 months, with the option to restart if the cancer progresses, is not worse than continuing ARPI treatment. The goal is to reduce side effects and costs while maintaining effective disease control. Participants will be randomly assigned after completing 12 months of ARPI treatment to one of two groups one group will continue androgen deprivation therapy ADT combined with ARPI, while the other will stop ARPI after 12 months but may restart it if a confirmed rise in prostate-specific antigen PSA occurs. The PSA confirmation sample must be taken at least four weeks after the initial rise. Treatment will be monitored closely according to these protocols. During the study, participants will be followed for up to 6 years, including 5 years after randomization to track clinical progression-free survival. Researchers will regularly assess disease status, treatment effects, and possible side effects. The study includes regular visits and monitoring to evaluate how long patients remain free from disease progression while comparing the two treatment approaches.

Age: 18Years +MALEPhase 3
26 locations
S

Actively Recruiting

Researchers are studying patients with non-metastatic stage II colon cancer who are part of the Dutch ColoRectal Cancer cohort PLCRC and who consented to additional blood samples. The study aims to evaluate how many patients with detectable circulating tumor DNA ctDNA after surgery begin adjuvant chemotherapy. This observational and interventional trial includes patients who do not have a standard indication for chemotherapy and involves a randomized design to compare ctDNA-guided treatment with standard care. Patients are randomly assigned to one of two groups the ctDNA-based treatment group or the standard care group. In the ctDNA group, blood samples taken after surgery are analyzed for ctDNA. Those with detectable ctDNA are offered 3 months of adjuvant chemotherapy using CAPOX a combination of fluoropyrimidine and oxaliplatin. Patients without detectable ctDNA receive routine follow-up care. The standard care group receives routine follow-up without knowledge of their ctDNA results. Participants will have blood collected before surgery, after surgery, and during follow-up. Researchers will monitor who starts chemotherapy within 8 to 12 weeks after surgery and will track recurrence rates, disease-free survival, overall survival, time to recurrence, quality of life, and cost-effectiveness over several years. Follow-up assessments occur up to 10 years, allowing detailed long-term evaluation of treatment impact and patient outcomes.

Age: 18Years +All GendersPhase Not Applicable
29 locations
R

Actively Recruiting

This research aims to evaluate the effectiveness and safety of different doses of the drug AP31969 in reducing the burden of Atrial Fibrillation AF. The trial is a randomized Phase 2 study comparing several doses of AP31969 against a placebo in adults diagnosed with paroxysmal or persistent AF. Participants are carefully selected based on their AF history and burden, and the study monitors heart rhythm using implanted devices. Participants are assigned randomly to one of five groups receiving oral tablets twice daily for 12 weeks AP31969 at doses of 100 mg, 200 mg, 350 mg, or 500 mg added later, or a placebo without active properties. The study consists of three main periods screening up to 4 weeks, treatment 12 weeks, and a follow-up period of 30 days, totaling about 20 weeks. During the study, participants receive an implantable loop recorder to continuously monitor heart rhythm. Throughout the trial, participants undergo several assessments including blood and urine tests, electrocardiograms, and continuous rhythm monitoring via the loop recorder. The main outcome measured is the AF burden from weeks 2 to 12, with additional measures including the number of AF episodes, quality of life changes, and ventricular tachycardia episodes. Safety and adherence are closely monitored, and the follow-up period helps assess sustained effects and participant well-being after treatment ends.

Age: 18Years +All GendersPhase 2
46 locations
E

Actively Recruiting

This research aims to evaluate the continuation of the same systemic therapy after applying local ablative therapy LAT for patients with metastatic breast cancer that shows oligoprogression during palliative treatment. Oligoprogression is defined as limited progression in one or two lesions and this study focuses on patients with invasive breast cancer who have metastatic disease and are receiving systemic therapy. The study is a phase 2 interventional trial sponsored by The Netherlands Cancer Institute. Participants will receive local ablative therapy targeted at the progressing lesions, which may include surgery, stereotactic ablative radiotherapy SABR, or percutaneous radiofrequent ablation. The choice of LAT depends on the lesions location and will follow standard care decided by the treating team. The systemic therapy, which can be endocrine, targeted, chemotherapy, or immune-checkpoint blockade, will continue unchanged during the study. Throughout the study, patients will be monitored with imaging to confirm oligoprogression and assess lesion response. Outcome measures include the number of patients free of disease progression at 6 months, overall survival, time to next treatment, and complications from LAT. The study involves ongoing follow-up for up to 120 months to observe long-term outcomes. Participants will undergo radiological imaging, including FDG-PET-CT scans, and clinical assessments to track treatment effects and safety.

Age: 18Years +All GendersPhase 2
7 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are studying how adults with autism spectrum disorder ASD make eye contact during both formal and informal conversations. The study aims to understand how the type of conversation affects eye contact in terms of length, frequency, and overall behavior. It also seeks to measure physiological responses to eye contact to see if it causes increased, decreased, or unchanged stress levels, and to compare how people with ASD respond to others eye contact versus their own. The study uses an exploratory mixed methods design with two parts. In the first part, a researcher has a conversation with an adult with ASD, including a formal and informal phase. During this conversation, hidden recordings capture the participants eye behavior while skin conductance and eye contact measures are recorded without the participant knowing the focus on eye contact. In the second part, the participant and researcher watch the hidden recordings together while skin conductance is recorded again and specific behaviors are noted. The setup and physiological measurements are tested beforehand. Participants will be evaluated through video, audio, and skin conductance recordings to assess frequency and duration of eye contact, arousal during eye contact, and reflection on their own eye contact. The study will measure both behavioral and physiological data during interactions and review phases. The research involves adults aged 18 to 65, including neurotypical individuals and those with ASD, and participation includes interaction sessions and follow-up observation of recorded behaviors.

Age: 18Years - 65YearsAll GendersPhase Not Applicable
1 location

1-10 of 42

1